Progenics Pharmaceuticals Inc. (PGNX)

5.06
NASDAQ : Health Technology
Prev Close 4.85
Day Low/High 4.86 / 5.11
52 Wk Low/High 3.42 / 6.31
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 86.62M
Market Cap 420.12M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Progenics Sends Letter To Shareholders

Progenics Sends Letter To Shareholders

Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders Urges Shareholders to Sign and...

Lifshitz & Miller LLP Announces Investigation Of Arotech Corporation, Dova Pharmaceuticals, Inc., Highlands Bankshares, Inc., Progenics Pharmaceuticals, Inc., Proteon Therapeutics, Inc., Roan Resources, Inc., SemGroup Corporation And The Stars Group Inc.

Lifshitz & Miller LLP Announces Investigation Of Arotech Corporation, Dova Pharmaceuticals, Inc., Highlands Bankshares, Inc., Progenics Pharmaceuticals, Inc., Proteon Therapeutics, Inc., Roan Resources, Inc., SemGroup Corporation And The Stars Group Inc.

NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Arotech Corporation (ARTX) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of Arotech to Greenbriar Equity Group, L.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

NEW YORK, Oct. 4, 2019 /PRNewswire/ --  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Progenics Pharmaceuticals, Inc.

Possible M&A Surrounds These 3 Stocks

Possible M&A Surrounds These 3 Stocks

M&A activity has generally slowed.

INVESTOR ALERT: Monteverde & Associates PC Announces An Investigation Of The Following Merger

INVESTOR ALERT: Monteverde & Associates PC Announces An Investigation Of The Following Merger

NEW YORK, Oct. 3, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Chardan Heathcare Acquisition...

Shareholder Alert: Ademi & O'Reilly, LLP Investigates Whether Progenics Pharmaceuticals, Inc. Has Obtained A Fair Price In Its Sale To Lantheus Holdings, Inc.

Shareholder Alert: Ademi & O'Reilly, LLP Investigates Whether Progenics Pharmaceuticals, Inc. Has Obtained A Fair Price In Its Sale To Lantheus Holdings, Inc.

MILWAUKEE, Oct. 3, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Progenics (Nasdaq: PGNX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Progenics to Lantheus.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Progenics Pharmaceuticals, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Progenics Pharmaceuticals, Inc.

NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc.

Velan Comments On Announced Sale Of Progenics To Lantheus

Velan Comments On Announced Sale Of Progenics To Lantheus

Velan Capital, L.P.

Lantheus and Progenics Sink After Striking All-Stock Deal

Lantheus and Progenics Sink After Striking All-Stock Deal

Lantheus will acquire oncology medicine developer Progenics Pharmaceuticals in an all-stock deal.

Lantheus To Acquire Progenics To Form A Leading Precision Diagnostics Imaging And Therapeutics Company

Lantheus To Acquire Progenics To Form A Leading Precision Diagnostics Imaging And Therapeutics Company

Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc.

First Week Of May 2020 Options Trading For Progenics Pharmaceuticals (PGNX)

First Week Of May 2020 Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the May 2020 expiration.

Progenics Confirms Notice Of Preliminary Consent Solicitation By Velan Capital, L.P. Despite Repeated Efforts By The Company To Reach A Reasonable Resolution

Progenics Confirms Notice Of Preliminary Consent Solicitation By Velan Capital, L.P. Despite Repeated Efforts By The Company To Reach A Reasonable Resolution

Board Has Made Numerous Corporate Governance Enhancements Reflecting Feedback From Shareholders No Shareholder Action Required at this Time NEW YORK, Sept.

These 2 Biotech Stocks Are Seeing Insider Buying Activity

These 2 Biotech Stocks Are Seeing Insider Buying Activity

We're focused on Progenics Pharmaceuticals and Aerie Pharmaceuticals.

Progenics Pharmaceuticals Announces Presentation At The International Conference On Immunotherapy Radiotherapy Combinations

Progenics Pharmaceuticals Announces Presentation At The International Conference On Immunotherapy Radiotherapy Combinations

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.

Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results

Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results

Progenics' Self-Proclaimed "Master[s] of Commercialization" Continue to Underperform Under the Troubling Status Quo and Neglect to Publicly State Metrics and Goals to Assess Future Performance

Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results And Business Update

Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results And Business Update

Recorded First Revenues for AZEDRA ®; CMS Grants New Technology Add-On Payment of Up to $98,150 per Therapeutic Dose for Inpatient Use of AZEDRA Enrollment Completed Ahead of Schedule in Phase 3 CONDOR Trial of PyL TM ( 18F-DCFPyL); Topline Data Expected...

Progenics Pharmaceuticals Announces Additional Governance Enhancements

Progenics Pharmaceuticals Announces Additional Governance Enhancements

Board Accepts Resignations of Directors Peter J. Crowley and Michael D.

CMS Grants New Technology Add-On Payment For Inpatient Use Of AZEDRA® (iobenguane I 131)

CMS Grants New Technology Add-On Payment For Inpatient Use Of AZEDRA® (iobenguane I 131)

Provides Additional Medicare Reimbursement up to 65% of the Cost of AZEDRA Prescribed for Inpatient Medicare Patients

Progenics Pharmaceuticals Shares Cross Below 200 DMA

Progenics Pharmaceuticals Shares Cross Below 200 DMA

In trading on Monday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $4.83, changing hands as low as $4.72 per share.

Progenics Pharmaceuticals Completes Enrollment In Pivotal Phase 3 CONDOR Study Of PyL For The Detection Of Prostate Cancer

Progenics Pharmaceuticals Completes Enrollment In Pivotal Phase 3 CONDOR Study Of PyL For The Detection Of Prostate Cancer

Top-line Data Now Expected by Year End Reaches Alignment with FDA on Regulatory Path; Company to Submit NDA Following Positive CONDOR Data Completed Enrollment in Pivotal Phase 3 Trial in Eight Months NEW YORK, Aug.

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results And Business Update Call For August 9

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results And Business Update Call For August 9

NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals Announces Collaboration With Veterans Affairs On The AI Research Program For Medical Image Analysis

Progenics Pharmaceuticals Announces Collaboration With Veterans Affairs On The AI Research Program For Medical Image Analysis

The collaboration with VA Greater Los Angeles Healthcare System is nation's first to validate deep learning algorithms in medical imaging of veterans with prostate cancer

Velan Announces Progenics Pharmaceuticals Stockholders Support Its Campaign For Change At Progenics' 2019 Annual Meeting

Velan Announces Progenics Pharmaceuticals Stockholders Support Its Campaign For Change At Progenics' 2019 Annual Meeting

Final Voting Results Confirm that Approximately Two-Thirds of the Votes Cast Were Against the Re-Election of Peter Crowley and Michael Kishbauch

Following These 2 Small-Caps Into Earnings

Following These 2 Small-Caps Into Earnings

I'm looking forward to hearing from Progenics Pharmaceuticals and Builders FirstSource.

TheStreet Quant Rating: D (Sell)